As Vice President of Development Operations at Tevard Biosciences, Paul Kaplan is responsible for advancement the development portfolio. He has over 30 years’ experience in the biotechnology industry leading functional and cross-functional drug development teams in multiple therapeutic areas.

Before Tevard, Paul was Executive Director of Program Management at CRISPR Thereapeutics (NASDAQ: CRSP) and held multiple positions with responsibilities in Alliance Management, early development of allogeneic CAR-T cell therapeutics and AAV manufacturing as well as in building out an award winning GMP manufacturing plant for gene edited cell therapies. Prior to CRISPR, he had various positions in Program Management and research at Alzheon, Genzyme Corporation and Creative BioMolecules after joining industry from a joint faculty appointment at the Dana Farber Cancer Institute and Harvard Medical School and a post-doctoral fellowship at the Salk Institute for Biological Studies.

Paul holds a PhD from The University of Texas Southwestern Medical Center in Dallas, an MBA from Northeastern University in Boston and an AB from The University of Pennsylvania in Philadelphia.